Hoechst Marion Roussel and Rhône-Poulenc Rorer announced they plan to boost their combined sales force to 4,000 reps.
In an update to the recent announcement that they plan to merge, Hoechst Marion Roussel, Germany, and Rhône-Poulenc Rorer, France, announced they plan to boost their combined sales force to 4,000 reps.
Currently, their combined sales forces total 3,400 reps. While that number might have seemed large two years ago, it places the sales force of the future consolidated company, Aventis Pharma, in sixth place in the United States.
"These substantial marketing resources will enable Aventis Pharma to leverage fast-growing products," the companies said in a formal statement.
Sales reps will be responsible for promoting current products, such as Hoechst Marion Roussel's antiallergy medicine Allegra and Rhône-Poulenc Rorer's low-molecular weight heparin Lovenox and anticancer drug Taxotere.
In the future, pending FDA approval, Aventis reps could also be responsible for promoting the anti-osteoporosis medicine Actonel, the rheumatoid arthritis medicine Arava, the anti-infective Synercid and drugs for cardiovascular diseases and psychoses.
Presumably, the increase in the sales force will take place upon completion of phase one of a two-stage merger.
In phase one, the two companies will form a 50/50 joint venture of pharmaceutical and agricultural activities. In phase two, which should take place in three years, the parent companies will fully merge, bringing their shareholdings together.
Phase one of the merger, which must receive European regulatory approval, is scheduled for mid-1999. PR
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.